Media coverage about Veracyte (NASDAQ:VCYT) has been trending somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Veracyte earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.5268952619817 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities research analysts recently commented on VCYT shares. Zacks Investment Research upgraded shares of Veracyte from a “sell” rating to a “hold” rating in a research report on Friday, November 10th. Janney Montgomery Scott downgraded shares of Veracyte from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 7th. Piper Jaffray Companies downgraded shares of Veracyte from an “overweight” rating to a “neutral” rating in a research report on Tuesday, November 7th. Leerink Swann cut their target price on shares of Veracyte from $12.00 to $9.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 7th. Finally, ValuEngine downgraded shares of Veracyte from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $11.85.
Veracyte (VCYT) traded down $0.03 during trading on Wednesday, reaching $6.12. 14,214 shares of the company’s stock traded hands, compared to its average volume of 112,370. The company has a current ratio of 5.19, a quick ratio of 4.86 and a debt-to-equity ratio of 0.59. Veracyte has a 52-week low of $5.75 and a 52-week high of $9.80. The company has a market cap of $201.18, a price-to-earnings ratio of -7.52 and a beta of 1.63.
ILLEGAL ACTIVITY WARNING: “Veracyte (VCYT) Earning Somewhat Positive Media Coverage, Study Finds” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/07/veracyte-vcyt-earning-somewhat-positive-media-coverage-study-finds.html.
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.